30 results about "Virus infected cell" patented technology

The invention discloses an application of Rottlerin in preparation of a medicine for preventing and treating nervous necrosis virus. According to the application disclosed by the invention, the fact that the rotinidin has high binding energy to RGNNV capsid protein is found, the rotinidin without toxic concentration is selected to carry out an RGNNV virus infected cell experiment, and the result shows that the rotinidin inhibits the replication of the RGNNV virus in a dose-dependent manner. The safe dosage of Rottlerin is obtained according to the survival rate of zebrafish treated with different doses, the influence of Rottlerin on the survival rate of zebrafish infected with RGNNV is researched, and finally it is proved that Rottlerin has a remarkable treatment effect on zebrafish infected with RGNNV. Rottlerin provides a new natural small molecule drug choice for prevention and treatment of VNN diseases, and has important research and development value and development significance for prevention and treatment of nervous necrosis viruses.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting NKG2DL and secreting IL-10 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains a nucleic acid molecule of a chimeric antigen receptor encoding NKG2D and IL-10 or is prepared through an expression vector containing the nucleic acid molecule. The CAR-T cell expresses a chimeric antigen receptor targeting NKG2DL and can secrete a cell factor IL-10, the proliferation and effector functions of the CAR-T cell are promoted, and the killing activity on tumors is enhanced.

To provide methods and compositions for reducing virus titer and eliminating virus-infected cells from an individual.SOLUTION: Provided is the use of an anti-CD24 antibody in the production of medicament for use in a method for reducing hepatitis virus in an individual, where the method comprises: contacting the individual to a therapeutically effective dose of the anti-CD24 antibody for a period of time sufficient to reduce the amount of hepatitis virus, where the hepatitis virus is one or more of hepatitis B virus (HBV) and hepatitis delta virus (HDV).SELECTED DRAWING: None

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

The application provides a benzene [d] isoxazole compound and an application thereof. The compound has the structure shown in the following formula I. The benzene [d] isoxazole compound provided by the application can induce degradation of BET protein and / or GSPT1 protein, and has an anti-proliferation effect on cancer cells. Therefore, the compound and the composition provided by the application can be used for preparing a drug for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and the like.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The application discloses a kind of targeted exosome chimeric antigen receptor molecules for treating HIV infection and its application, belong to the field of biological medicine technology.The application is packaged into targeted exosome by coding anti-HIV CAR mRNA directionally.The nano antibody sequence of targeted CD3, CD4, CD8+T receptor on T cell is fused to the N-terminal of LAMP-2B to construct specific targeting plasmid, so that the targeted peptide is expressed on the surface of exosome membrane, the expression plasmid containing RNA binding protein L7A and exosome tag protein CD63 is constructed, and the exosome loaded with CAR mRNA and targeted to T cell is obtained by three-plasmid co-transfection of HEK293F cells containing C / D box CAR plasmid.The exosome can construct human CAR-T cell when incubated with PBMC in vitro or back into humanized mouse in vivo, and has significant killing virus infected cell activity.

The present disclosure relates to the field of methods for culturing virally-infected cells. More particularly, this disclosure relates to methods of culturing cells with an influenza A virus. The disclosure relates further to impact of certain culture factors such as trypsin concentration, pH levels, incubation time, and combinations thereof on the production of viral proteins, particularly haemagglutinin.

[Problem] To provide an antiviral oligonucleotide that acts on cells infected by viruses having multiple RNA genomes, exhibiting an antiviral effect, and does not tend to the emergence of resistant viruses, and a pharmacological composition thereof. [Solution] An oligonucleotide that takes on a G-quadruplex structure that inhibits the binding of the genomic RNA and nucleocapsid (N) protein of a virus having an RNA genome, the antiviral oligonucleotide suppressing proliferation of the virus by contact with virus-infected cells, and a pharmacological composition thereof are used.

Methods for providing a vaccine composition capable of effectively inducing a systemic immune response and / or a topical immune response upon administration wherein the composition comprises a human leukocyte antigen class I (HLAI) restrictive epitope selected from the viral pathogen non-virion constituent protein (non-VIP) and thus elicits a CD8T cell response specific against viral infected cells.

The application belongs to the technical field of biological medicine, and provides a recombinant type III human collagen peptide for resisting HPV infection and a preparation method and application thereof, an amino acid sequence of which is a coding sequence of positions 991-1032 of type III human collagen UniProtKB: P02461 repeated three times, named as ATHPV3, and an amino acid sequence of which is shown as SEQ ID NO. 1. After expression and purification, the recombinant type III human collagen peptide with a molecular weight of about 13 kD is obtained, can be specifically combined with HPV 16 / 18 L1 protein, has multiple hydrogen bond actions, and can inhibit pseudo-virus infection of 293T cells at high and medium concentrations. The application successfully obtains a recombinant type III human collagen peptide with good purity, which can be combined with HPV 16 / 18 L1 and can effectively inhibit HPV 16 / 18 pseudo-virus infection of 293T cells, and provides an effective candidate drug for preventing and treating HPV infection.

The application provides a kind of 2,6-piperidinedione derivatives and preparation method and application thereof.The compound has the structure shown in the following formula I, formula II or formula III:2,6-piperidinedione derivatives described in the application can induce the degradation of GSPT1 protein, and have cytotoxic effect on cancer cells.Therefore, the compound and composition provided by the application can be used for preparing drugs for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and other related diseases.

A method of culturing cells for vaccine production comprises culturing cells in the presence of microcarriers with cell culture media and infecting the cells with a virus. The microcarrier comprises a bead and a coating. The coating comprises a thermo-responsive polymer having a lower critical solution temperature (LCST) of between about 20 °C and about 34 °C. The cells adhere to the coating of the microcarrier at a temperature above the LCST. The microcarrier comprises a polymeric bead, and a hydrophobic polymer. The hydrophobic polymer is a block copolymer which is connected to the bead by a covalent bond or by physical adsorption. The block copolymer comprises at least one hydrophobic block and at least one thermo-responsive block.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

The invention discloses a reagent and a kit for detecting EB (Epstein-Barr) virus infection and a method for detecting EB virus infected cell lineage, and belongs to the field of medical diagnosis. The technical problem to be solved by the invention is how to accurately locate different cell lineages of EBER + cells. The reagent for detecting EB virus infection disclosed by the invention contains an EBV probe and an antibody for marking a cell lineage, the sequence of the EBV probe is shown as SEQ ID No.1 and SEQ ID No.2, and the antibody for marking the cell lineage is a CD3 antibody, a CD20 antibody and / or a CD56 antibody. The reagent and the kit for detecting EB virus infection can be used for simultaneous marking of EBER genes and antigen proteins, accurate positioning of different cell lineages of EBER + cells is achieved, and cell lineage positioning of EB virus infection is further achieved.

This invention belongs to the field of virus-infected cell line technology, and particularly relates to a striped field mouse lung cell line and its applications. The striped field mouse lung cell line has the accession number CCTCC NO: C2025268. The AaL-09W cell line (including primary and passaged cells) provided by this invention has multiple advantages, including high sensitivity to Hantavirus, high replication efficiency, high isolation success rate, closer resemblance to the host's natural environment, passage stability, and easy scaling-up. It provides a reliable cellular tool and an efficient, reliable, and scalable experimental platform for the isolation, identification, in vitro culture, titer determination, infection mechanism and pathogenesis research, new drug screening, and vaccine development of Hantavirus, meeting the needs of efficient culture and multi-scenario applications of HTNV and related Hantaviruses.

The application discloses a compound with a structural formula I, wherein the compound has good 3CL protease inhibitory activity, has significant proliferation inhibitory activity on virus-infected cells, and has potential application value in treating diseases related to virus infection. The compound has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential drug compound.

The invention discloses a method for predicting a CAR-T killing effect in vitro based on NO probe cell imaging, and relates to the field of immunotherapy curative effect evaluation. The method comprises the following steps: detecting the expression quantity of CD58 in cells through virus infection, a protein imprinting experiment and a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) experiment, then incubating tumor cells in vitro through an NO fluorescent probe, imaging to detect a fluorescent signal, finally co-culturing CAR-T and the tumor cells in vitro, and evaluating the killing effect through flow cytometry. The expression level of CD58 is reflected through the intensity of a fluorescence signal generated when the NO probe acts on tumor cells, and the killing effect of CAR-T is reflected through the expression level of CD58. According to the invention, the NO probe technology is utilized for simple, sensitive, rapid and visual detection, and the killing activity of the CAR-T is evaluated in vitro, so that a basis is provided for follow-up in-vivo killing treatment of the CAR-T.

The invention provides a high-throughput screening method of an anti-Nipah virus drug. The method comprises the following steps: firstly, completing drug gradient dilution and planking pretreatment in a BSL-2 laboratory; then carrying out virus infection, cell culture and 72-hour incubation in the BSL-4 core region; the method comprises the following steps: carrying out rapid and low-cost visual preliminary screening on a whole-plate sample through crystal violet dyeing, and selectively carrying out TRIzol LS inactivation treatment on a small amount of potential effective sample supernatant; after the inactivated sample is transferred to a BSL-2 laboratory, the virus copy number is accurately quantified by adopting a qRT-PCR technology, and finally the drug inhibition ratio and the EC50 value are calculated. According to the method, through a staged screening strategy, on the premise of ensuring biological safety, the screening flux is greatly improved, the detection cost is reduced, and a reliable solution is provided for drug screening of high-pathogenicity pathogenic microorganisms.

The present application belongs to the field of prevention and control of aquatic pathogenic microorganisms, and particularly relates to a fish rhabdovirus binding protein and a preparation method and application thereof. The protein can efficiently bind to the site of fish rhabdovirus binding to a host cell receptor, effectively block the invasion channel of fish rhabdovirus invading a host cell, thereby blocking virus infection of a cell and avoiding virus replication and proliferation in a host body. The fish rhabdovirus binding protein provided by the present application has a high-efficiency anti-rhabdovirus effect, and a premixed feed additive prepared by taking the protein as an active material can significantly improve the anti-rhabdovirus capacity of fry, is safe and non-polluting, can be applied on a large scale, and can further improve the economic benefits of fish culture.

The invention discloses an application of cis-BBP in inactivation of viruses with envelope structures. Any one of the following applications of the cis-BBP comprises an application of the cis-BBP in photodynamic inactivation of the virus with the envelope structure, an application of the cis-BBP in preparation of a product for preventing and treating the virus with the envelope structure, and an application of the cis-BBP in preparation of a product for inhibiting cells infected by the virus with the envelope structure. According to the application of the cis-BBP in photodynamic inactivation of the virus with the envelope structure, the antiviral efficiency is high, and a broad-spectrum antiviral strategy for the virus with the envelope structure is developed. The broad-spectrum antiviral ability of the cis-BBP is explored by utilizing the characteristics of the cis-BBP, and the action effect of the cis-BBP on various viruses is clarified. The cis-BBP shows antiviral activity and excellent biocompatibility in vivo. When applied to transportation and packaging, it shows significant potential in controlling virus propagation.

The present disclosure provides compositions and methods for inhibiting herpesvirus replication in a cell infected with herpesvirus. The composition includes a double stranded DNA molecule including a sequence of a cis regulatory sequence (crs) of a herpesvirus, wherein the crs is flanked on 5′ end by a first sequence of at least 2 base pairs and on the 3′ end by a second sequence of at least 2 base pairs.

In various embodiments methods of utilizing gene drive constructs in asexual organisms such as viruses are provided. In certain embodiments the methods involve transfecting or infecting a cell with a modified DNA virus containing a gene drive construct; and infecting the cell with the target virus where the genome of said target DNA virus is modified by insertion of the gene drive construct into the genome of the target DNA virus and a population of modified target viruses (containing the gene drive construct) is produced.

The present disclosure relates to the field of methods for culturing virally-infected cells. More particularly, this disclosure relates to methods of culturing cells with an influenza A virus. The disclosure relates further to impact of certain culture factors such as trypsin concentration, pH levels, incubation time, and combinations thereof on the production of viral proteins, particularly haemagglutinin.

The present invention provides an antibody that binds to an extracellular domain of TMPRSS2, capable of inhibiting beta coronavirus infection of cells, or an antigen-binding fragment thereof, and a composition including the antibody or an antigen-binding fragment thereof.

The invention discloses a bovine nodular skin disease subunit vaccine based on P122-Fc fusion protein, and belongs to the technical field of veterinary biological products. The bovine nodular dermatosis subunit vaccine disclosed by the invention comprises a P122-Fc fusion protein and a water-in-oil-in-water type multiple emulsion adjuvant MONTANIDEISA 206 VG. According to the invention, a genetic engineering subunit vaccine technical route is adopted, the vaccine components are only recombinant proteins and adjuvants and do not contain any forms of live viruses, so that the risks of virulence reversion and vertical transmission are fundamentally eradicated; high safety is successfully combined with a high intensity, Th1 biased immune response. According to the scheme, a high-titer body fluid antibody is excited, and the body fluid antibody is necessary for eliminating virus infected cells. Systematic target animal safety tests (including pregnant cow over-dose inoculation) prove that no abortion and no significant adverse reaction exist, safe immunity to sensitive groups such as pregnant cows is achieved, and the problems that existing mainstream attenuated live vaccines have potential virulence enhancement risks, may cause abortion to pregnant cows, and are poor in immunity to pregnant cows are thoroughly solved. And the application of the feed additive in key livestock groups is strictly limited.

This document relates to methods and materials for treating viral infections. For example, this document provides viral minigenomes designed to express one or more therapeutic polypeptides within virus infected cells to reduce the production of infecting virus, thereby treating the virus infection.

Provided herein, inter alia, is a recombinant herpesvirus vector genome including a heterologous herpesvirus Infected Cell Polypeptide 0 (ICP0) gene, a polynucleotide comprising the recombinant herpesvirus vector genome, and a host cell including the recombinant herpesvirus vector genome. The recombinant herpesvirus vector genome provided herein including embodiments thereof is contemplated to be useful for expressing a transgene in the host cell. In embodiments, the recombinant herpesvirus vector genome provided herein including embodiments thereof causes no detectable cellular toxicity to the host cell.

A method is provided for reducing cytokine secretion in virus-infected cells through treatment with specific alkylamides. The method includes identifying a cell infected with a rhinovirus or influenza virus and administering one or more alkylamides, such as Dodeca-2(E),4(E)-Dienoic acid isobutylamide, to reduce cytokine release, particularly interleukin-8 (IL-8). In certain embodiments, the alkylamides are in purified form and may be derived from Echinacea purpurea. The method may further comprise measuring IL-8 secretion to assess efficacy of the treatment. Another aspect provides a screening method for identifying specific alkylamides effective against respiratory virus infections by comparing cytokine secretion levels between infected cells treated with purified alkylamides and those treated with Echinacea purpurea ethanolic extract. Alkylamides demonstrating reduced cytokine secretion and a selectivity index greater than 10 are identified as therapeutic candidates for mitigating cytokine-mediated inflammatory responses in respiratory viral infections.

The present invention relates to a computer-implemented method (100) for training a machine learning model to label images of a plurality of cells as having or not having virus-induced cytopathic effect, comprising the steps of: a. Obtaining a training set including a plurality of images of virus-infected cells and uninfected cells, wherein the training set is annotated with labels indicating the presence or absence of virus-induced cytopathic effect for each image, and wherein the training set includes images of at least a set of cells infected by a one virus type and a set of cells infected by a second virus type; b. Training the machine learning model on the training set to predict whether an image of a plurality of cells contains virus-induced cytopathic effect or not, based on features extracted from the images. The present invention relates also to a computer-implemented method for labelling an image of a plurality of cells as having or not having virus-induced cytopathic effect.